InMed Pharmaceuticals Inc. Share Price & Technical Analysis
INM · $1.72 (-0.58%)
Healthcare / Drug Manufacturers - Specialty & Generic
$1.72
-0.58%
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturi…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
143% return in May, 4% avg return in past 3 year May month.
116% return in 2026, -95% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | -18% | -25% | 17% | 143% | – | – | – | – | – | – | – | 116% |
| 25 | -34% | -6% | -28% | 50% | -17% | -43% | -23% | -8% | 5% | -14% | -32% | -15% | -164% |
| 24 | -10% | 22% | -12% | -26% | 16% | -7% | -34% | 103% | -34% | 6% | -19% | 9% | 15% |
| 23 | -6% | -28% | -20% | 11% | 12% | -37% | 24% | -27% | -13% | -33% | -18% | 0% | -134% |
| 22 | -12% | -19% | 0% | -1% | -17% | -38% | -16% | -40% | 13% | -54% | -13% | -23% | -221% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Exhausted
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.15M
P/E ratio
—
52W high
$7.98
52W low
$0.57
Volume
6,60,368
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is InMed Pharmaceuticals Inc. share price today?
- InMed Pharmaceuticals Inc. (INM) last traded around $1.72 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does INM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for INM. Download the app for real-time alerts.
- How can I analyze InMed Pharmaceuticals Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.